Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis | Zendy

AI Assistant Blog Pricing

Open Access

Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis

Author(s) -

Daniel Crespin,

Jerome J. Federspiel,

Andrea K. Biddle,

Daniel E Jonas,

Joseph S. Rossi

Publication year - 2011

Publication title -

carolina digital repository (university of north carolina at chapel hill)

Language(s) - English

DOI - 10.17615/qj8f-ph19

Subject(s) - ticagrelor , acute coronary syndrome , medicine , secondary prevention , cardiology , intensive care medicine , myocardial infarction

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.